Evaluation of HPRT Gene mutation and Comet Assay in Some Breast Cancer Patients Undergoing Radiotherapy

Abstract

Introduction: Radiotherapy is a toxic cellular treatment that destroys rapidly dividing cells such as cancer

cells. The strategy for HPRT mutation examination in human’s cells was commonly used to establish in vivo

history along with mutation rates in children and adults inhabitants subjected to experienced and unfamiliar

external mutagens. As just a practical approach to human biosurveillance studies, the comet assay has

been introduced over the past years as biomarker to identify ionizing radiation Consequences with Patients

undergoing radiotherapy in breast cancer.

Materials and Method: This study was carried out on thirty Iraqi women patients with BC patients

undergoing radiotherapy about 20-30 Gy locally gamma cells at Al-Amel National Hospital for cancer

Management in Baghdad during time 2-13 years, non-smokers and non- alcoholic, aged (35-55 year),

with stage (grade) I-III, as well as thirty apparently healthy individuals females collected randomly from

population living Baghdad, Old age (35-55) Which are non-alcoholic non-smokers as group of control.

Around the ongoing research comet-test and hprt mutation test could be applied to study damages in DNA

for genetic two endpoints For patients with cancer throughout radiation therapy.

Results: The present study showed significant increase (p<0.05) in the HPRT gene mutation assay for the

in breast cancer patients undergoing radiotherapy as compared with the control group. Also there were

found that the values of comet tail moment and tail length was increased significantly (p<0.05) in the human

lymphocyte in these for breast cancer patients undergoing radiotherapy as compared with the control group.

Conclusions: Present results revealed that there is a probability of utilizing human lymphocytes changes as

useful biodosimetric markers for the detection of human exposure to ionizing radiation, the data gathered

also demonstrated the utility of the HPRT gene mutation and (Alkaline) comet test as just a precise alternative

biological marker for routine preventative care of cancer patients receiving radiation therapy.